Ghebreyesus, T., WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available: www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 Accessed June, 2020.
Johns Hopkins Center for Systems Science and Engineering. Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE. Available: https://coronavirus.jhu.edu/. (Accessed 29 March 2020)
Secure-IBD Database. Available: https://covidibd.org/. (Accessed 29 March 2020)
ESPGHAN: Porto and IBD Interest Group. ESPGHAN. Available: www.espghan.org/about-espghan/committees/gastroenterology/working-groups/porto-and-ibd-interest-group/. (Accessed 29 March 2020)
Fitch, K., (eds.) The Rand/UCLA appropriateness method user's manual, 2001, RAND, Santa Monica.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. Cell 181 (2020), 271–280.
Xiao, F., Tang, M., Zheng, X., et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 158 (2020), 1831–1833.
Ianiro, G., Mullish, B.H., Kelly, C.R., et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol 5 (2020), 430–432.
Richardson, P., Griffin, I., Tucker, C., et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395 (2020), e30–e31.
Channappanavar, R., Perlman, S., Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39 (2017), 529–539.
Russell, C.D., Millar, J.E., Baillie, J.K., Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395 (2020), 473–475.
Cheng, K.-W., Cheng, S.-C., Chen, W.-Y., et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res 115 (2015), 9–16.
Wu, C., Chen, X., Cai, Y., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, 2020 Mar 13 [Epub ahead of print].
Wang, D., Hu, B., Hu, C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 323 (2020), 1061–1069.
Chen, L., Liu, H.G., Liu, W., et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi, 43, 2020, E005.
Li, C.K., Wu, H., Yan, H., et al. T cell responses to whole SARS coronavirus in humans. J Immunol 181 (2008), 5490–5500.
A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Register (ChiCTR). Available: www.chictr.org.cn/showprojen.aspx?proj=49889. (Accessed 29 March 2020)
Ng, S.C., Hilmi, I.N., Blake, A., et al. Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting. Inflamm Bowel Dis 24 (2018), 2431–2441.
Byrareddy, S.N., Arthos, J., Cicala, C., et al. Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy. Science 354 (2016), 197–202.
Uzzan, M., Tokuyama, M., Rosenstein, A.K., et al. Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. Sci Transl Med, 10, 2018.
Ghosh, S., Gensler, L.S., Yang, Z., et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn's disease: an integrated analysis of phase II/III clinical development programs. Drug Saf 42 (2019), 751–768.
Xu, X., Han, M., Li, T., et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv, 2020, 12.
Roche to start phase III trial of Actemra in Covid-19 patients. Clinical Trials Arena. Available: www.clinicaltrialsarena.com/news/roche-actemra-covid-19-trial/. (Accessed 29 March 2020)
Ben-Horin, S., Van Assche, G., Chowers, Y., et al. Pharmacokinetics and immune reconstitution following discontinuation of thiopurine analogues: implications for drug withdrawal strategies. J Crohns Colitis 12 (2018), 1410–1417.
Dotan, I., Werner, L., Vigodman, S., et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 18 (2012), 261–268.
Lamba, M., Wang, R., Fletcher, T., et al. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol 56 (2016), 1362–1371.
Weinhold, K.J., Bukowski, J.F., Brennan, T.V., et al. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Immunol 191 (2018), 10–20.
